P-246. Abstract Title: Neuropsychiatric Outcomes Associated With PI- vs. INSTI-Based Regimens in People With HIV: A Propensity-Matched Cohort Study

Abstract Background Neuropsychiatric symptoms (NPS), including anxiety, depression, and cognitive impairment, are increasingly recognized as adverse outcomes among people living with HIV (PLWH). As antiretroviral therapy (ART) use expands and treatment duration increases, concerns have emerged about neuropsychiatric effects of specific ART regimens. This study compared the risk of NPS among users of protease inhibitor (PI)-based and integrase strand transfer inhibitor (INSTI)-based ART. Methods We conducted a retrospective cohort study using the TriNetX Research Platform, a global, federated, de-identified real-world data system. Adults (≥18 years) with HIV prescribed PI- or INSTI-based regimens between January 1, 2015, and December 31, 2022, were included. Patients with prior NPS were excluded. Before matching, 5,063 PI and 11,788 INSTI users were identified. Propensity score matching (1:1) on demographics and comorbidities produced balanced cohorts (n = 5,058 per group). Kaplan–Meier analysis evaluated risk of anxiety, depression, and cognitive impairment at 12, 18, 24, and 36 months. Results At each time point, the PI group had a significantly higher probability of remaining free from anxiety: 12 mo: 94.7% vs. 91.5% (p = 0.0002; RR = 0.74, 95% CI [0.63–0.87]) 18 mo: 91.9% vs. 89.9% (p = 0.00014; RR = 0.80 [0.69–0.92]) 24 mo: 90.3% vs. 87.5% (p = 0.0004; RR = 0.81 [0.71–0.92]) 36 mo: 88.9% vs. 86.5% (p = 0.0002; RR = 0.84 [0.75–0.93]) No significant differences were observed between the two groups for depression or cognitive impairment at any follow-up point. Subgroup analysis of individuals aged >65 years showed no significant differences in neuropsychiatric risk between treatment groups. Conclusion This large- scale real- world study among adults with HIV showed that PI based regimens were associated with a significantly reduced risk of anxiety at 12,18, 24, 36 months compared with INSTI based regimens. These findings highlight the importance of considering neuropsychiatric events when selecting ART regimens. Further research is needed to understand these associations and potential confounding factors. Disclosures All Authors: No reported disclosures

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.468
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-246. Abstract Title: Neuropsychiatric Outcomes Associated With PI- vs. INSTI-Based Regimens in People With HIV: A Propensity-Matched Cohort Study

Aimalohi Okpeku, Elvin T Price
Open Forum Infectious Diseases
HIV Research and Treatment
article

P-246. Abstract Title: Neuropsychiatric Outcomes Associated With PI- vs. INSTI-Based Regimens in People With HIV: A Propensity-Matched Cohort Study

Aimalohi Okpeku, Elvin T Price
article en

Abstract

Abstract Background Neuropsychiatric symptoms (NPS), including anxiety, depression, and cognitive impairment, are increasingly recognized as adverse outcomes among people living with HIV (PLWH). As antiretroviral therapy (ART) use expands and treatment duration increases, concerns have emerged about neuropsychiatric effects of specific ART regimens. This study compared the risk of NPS among users of protease inhibitor (PI)-based and integrase strand transfer inhibitor (INSTI)-based ART. Methods We conducted a retrospective cohort study using the TriNetX Research Platform, a global, federated, de-identified real-world data system. Adults (≥18 years) with HIV prescribed PI- or INSTI-based regimens between January 1, 2015, and December 31, 2022, were included. Patients with prior NPS were excluded. Before matching, 5,063 PI and 11,788 INSTI users were identified. Propensity score matching (1:1) on demographics and comorbidities produced balanced cohorts (n = 5,058 per group). Kaplan–Meier analysis evaluated risk of anxiety, depression, and cognitive impairment at 12, 18, 24, and 36 months. Results At each time point, the PI group had a significantly higher probability of remaining free from anxiety: 12 mo: 94.7% vs. 91.5% (p = 0.0002; RR = 0.74, 95% CI [0.63–0.87]) 18 mo: 91.9% vs. 89.9% (p = 0.00014; RR = 0.80 [0.69–0.92]) 24 mo: 90.3% vs. 87.5% (p = 0.0004; RR = 0.81 [0.71–0.92]) 36 mo: 88.9% vs. 86.5% (p = 0.0002; RR = 0.84 [0.75–0.93]) No significant differences were observed between the two groups for depression or cognitive impairment at any follow-up point. Subgroup analysis of individuals aged >65 years showed no significant differences in neuropsychiatric risk between treatment groups. Conclusion This large- scale real- world study among adults with HIV showed that PI based regimens were associated with a significantly reduced risk of anxiety at 12,18, 24, 36 months compared with INSTI based regimens. These findings highlight the importance of considering neuropsychiatric events when selecting ART regimens. Further research is needed to understand these associations and potential confounding factors. Disclosures All Authors: No reported disclosures

Open Forum Infectious DiseasesVol. 13(Supplement_1)
Virginia Commonwealth University (US)
Good health and well-being
Openalex Percentile: Top 91%
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.